Stock Watch: Sanofi’s Vaccine Gap-Filling Aspirations

Exceeding €10bn In Vaccine Sales By 2030 Might Be A Stretch

Phase II studies of vaccines involve more variables than for drugs and these can be compounded by seasonality. This can make the time until vaccine approval longer than would be expected for drugs.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

Management consultants use gap analyses when helping biopharmaceutical companies target their therapeutic franchises’ opportunities relative to the unmet medical need and the competition. Sanofi’s vaccines investor event highlighted and addressed some of those gaps.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Stock Watch

More from Business